0.00 (0.00)
Prev Close 0.08
Open 0.08
Day Low/High 0.08 / 0.08
52 Wk Low/High 0.03 / 0.48
Volume 6.00K
Exchange OTC
Shares Outstanding 80.97B
Market Cap 6.48M
Div & Yield N.A. (N.A)

Cardax Launches First Product ZanthoSyn™

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that it has launched its first commercial product, ZanthoSyn ™, a safe anti-inflammatory for general health.

Cardax Enters Into Equity Purchase Agreement For Financing Of Up To $5 Million

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that it has entered into an Equity Purchase Agreement ("EPA") with an affiliate of Southridge LLC ("Southridge"), an institutional investor.

Cardax Awarded U.S. Inflammation Patent

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that it was awarded a U.

Cardax Product Candidates Demonstrate Superior Bioavailability Vs. Microalgal Astaxanthin In Monkey Study

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that its astaxanthin consumer health candidates CDX-085 and ASTX-1F demonstrated more than two and one-half times higher oral bioavailability than a leading microalgal...

Cardax Raises Additional $500,000 In Financing

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that it has closed on an additional $500,000 in equity financing, bringing the year-to-date amount raised in its issuer-directed unit offering to $1,125,000.

Cardax Initiates Monkey Study To Compare Bioavailability Of Patented Consumer Health Product Candidate CDX-085 To Microalgal Astaxanthin

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that it initiated a single-dose pharmacokinetic study in non-human primates (monkeys) to compare the bioavailability (exposure) of CDX-085, the Company's patented...

Capsugel: Http://

Capsugel and Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today a collaboration to develop unique astaxanthin products for the consumer health market.